-1,,,,, (, 100021) :[ ] -1 () [ ] ELISA 324 48 229, CEA CA125 NSE CYFRA21-1 SCC [ ] (P<0.001) (P<0.001) 71.3%96.5% CEA CA125 NSE SCC CYFRA21-1; (~ ), 5 ( :66.7% vs 47.6%, :71.7% vs 65.0%);6 77.1%83.3% [ ] : -1; ; :R734.2 :A :1004-0242(2015)05-0421-05 doi:10.11735/j.issn.1004-0242.2015.05.a015 Clinical Application of Serum Macrophage Inhibitory Cytokine-1 for Diagnosis of Lung Cancer SHEN Di,WANG Xiao-bing,CHE Yi-qun,et al. (Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021,China) Abstract:[Purpose] To investigate the clinical value of macrophage inhibitory cytokine-1 () as a serum tumor marker for the diagnosis of lung cancer. [Methods] The double antibody sandwich ELISA was used to detect serum level in 324 cases with lung cancer,48 cases with benign pulmonary disease and 229 healthy persons. Serum CEA,CA125,NSE,CYFRA21-1and SCC levels were also detected. [Results] concentration in lung cancer group was significantly higher than that in healthy persons group (P<0.001)and in benign disease group (P<0.001). The specificity and sensitivity of for lung cancer were 96.5% and 71.3% respectively. The sensitivity of for early stage of lung cancer was higher than that of CEA,CA125,NSE,SCC and CYFRA21-1 respectively. The sensitivity of for early stage of lung cancer (stage and stage ) was higher than the combination of the above five markers (stage :66.7% vs 47.6%; stage :71.7% vs 65.0%). The sensitivity for stage and stage reached 77.1% and 83.3% respectively in the combination of the six markers. [Conclusions] Serum level might be an ideal marker in diagnosis for lung cancer. Key words:macrophages inhibitory cytokine-1;tumor marker;lung cancer;diagnosis, -1()TGF-β,, :2014-12-29; :2015-01-27 : 863 (2008AA02Z415); (LC2012A12); (81441080) :,E-mail:qijun5610@126.com, [1] 2015 24 5 421
, 1.3 [2~5] 1 SPSS18.0, Kruskal-Wallis H, Mann-Whitney U ROC 1.1, P<0.05, 2 2011 9 2013 5 324, 206, 118, 27~87, 58.8±9.6 2.1 48, 20, 28, 23~75, 53.2±10.5 : 18,, 13, 8, 6 (P<0.001), 2, 1 (P<0.001) (Table 1), Table 1 Serum level in different patients(pg/ml) 229, 127, Group N P 25 P 50 P 75 102, 18~80, 51.4±11.4 Lung cancer 324 940.11 1346.28 1826.63 1.2 Benign disease 48 667.07 848.12 1239.80 Normal control 229 213.07 367.46 592.59 4ml; 30min,4 4000rpm 2.2 15min ; -80 (P=0.531),, (P=0.022) ELISA, (T) (N) (M)~ 450 450nm 655nm, ~ (P>0.05) (Table 2) [6] 2.3 Cobas601 ROC (area under (Roche) (CEA) curve,auc)0.912(95%ci:0.886~0.939) 125(CA125) (NSE) ROC, (CYFRA21-1), I2000 1000pg/ml, (Abbott) 71.3%96.5%(Figure 1) (SCC), 2.4,, 5ng/ml, CEA CA125 NSE SCC 35U/ml 18ng/ml 1.5ng/ml 3.3ng/ml, CYFRA21-1 ( 66.7% 16.2% 4.8% 97% ; 1.0% 13.3%22.9%, 71.7% 21.7%, 8.3% 5.0% 33.3% 48.3%, 68.4% 422 2015 24 5
Table 2 The association between levels and clinicopathological feature Clinicopathological features N P 25 P 50 P 75 Pathological type Squamous cell carcinoma 91 918.99 1383.53 1854.57 Adenocarcinoma 193 932.53 1245.43 1877.48 Small cell carcinoma 26 946.51 1341.63 1761.37 Sarcomatoid carcinoma 7 1039.66 2086.13 3680.03 Others* 7 1198.06 1574.50 1757.96 Differentiation High 57 786.09 1092.78 1486.87 Middle~Low 186 969.77 1371.61 1876.64 T stage T 1 54 764.40 1199.56 1591.20 T 2 167 964.35 1319.87 1875.79 T 3 48 877.22 1368.60 1809.53 T 4 31 1039.24 1391.50 2348.13 N stage N 0 142 959.63 1298.19 1853.57 N 1 ~N 3 150 878.68 13317.19 1778.63 Mstage M 0 240 900.19 1317.72 1940.06 M 1 78 1036.01 1426.50 1765.86 Stage ~ 164 927.04 1324.43 1868.38 ~ 160 962.73 1360.97 1862.63 Others:adenosquamous carcinoma and carcinoid tumor Sensitivity 1.0 0.8 0.6 0.4 0.2 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1-Specificity P value 0.531 0.022 0.344 0.672 0.308 0.629 CA125 NSE SCC CYFRA21-1 ( :66.7% vs 47.6%, : 71.7% vs 65.0%)(Table 3), 5 (100%,7/7), (73.1%,19/26), (71.4%,65/ 91), (68.9%,133/193)(Table 4) 3-1 (),, [7],,,, [2,3,8] Koopmann [9], (P<0.05) CA199 ROC 0.99 0.78;, CA199 ROC 0.81 0.74,, CA199 ( Figure 1 The ROC curve of in diagnosis of early stage lung cancer ) 39.2% 25.3% 21.5% [3,9,10] 31.6%53.2%,, 80.0% 56.3% 45.0% 31.3% 20.0%58.8%), (~ ), CEA 2015 24 5 423
Table 3 Tumor marker Total 1. 66.7 71.7 68.4 80.0 71.3 2.CEA 16.2 21.7 39.2 56.3 32.7 3.CA125 4.8 8.3 25.3 45.0 20.4 4.NSE 1.0 5.0 21.5 31.3 14.2 5.SCC 13.3 33.3 31.6 20.0 23.1 6.CYFRA21-1 22.9 48.3 53.2 58.8 43.8 Combined 2~6 47.6 65.0 83.5 86.3 69.1 Combined 1~6 77.1 83.3 97.5 98.8 88.6 Table 4 Tumor marker Sensitivity of and other 5 tumor markers in lung cancer with different stage Sensitivity of and other 5 markers in lung cancer with different pathological types Squamous cell carcinoma Adenocarcinoma Small cell Sarcomatoid carcinoma carcinoma 1. 71.4 68.9 73.1 100.0 2.CEA 20.9 40.4 26.9 14.3 3.CA125 19.8 21.8 15.4 14.3 4.NSE 15.4 7.8 61.5 28.6 5.SCC 44.0 16.1 0 14.3 6.CYFRA21-1 65.9 35.2 26.9 28.6 Combined2~6 82.4 66.3 69.2 42.9 Combined1~6 97.8 84.5 88.5 100.0 [4], SCC,,, SCC, ELISA, SCC, CYFRA21-1 19,, [13],, [11], 5,, (P<0.001), TNM, ROC 0.912, ROC, (~ ), 5 1000pg/ml, ( :66.7% vs 47.6%, : 96.5%71.3% 71.7% vs 65.0%) 6, 77.1% (P=0.022) 83.3%,, (T), (N) (M) ~ (P>0.05), TNM CEA CA125 NSE SCC CYFRA21-1,CEA NSCLC ; CEA [12] CA125 (P<0.01), ;,CA125, 40.18% [12] NSE,,NSE,, NSE, NSE [13], NSE, 5, 424 2015 24 5
[J].,2011,9(4):361-366.] [7] Lee DH,Yang Y,Lee SJ,et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells, by up-regulating the urokinase-type plasminogen activator : system [J]. Cancer Res,2003,63(15):4648-4655. [8] Welsh JB,Sapinoso LM,Kern SG,et al. Large-scale delineation [1] Groome PA,Bolejack V,Cruwley JJ,et al. The IASLC Lung Cancer Staging Project:validation of the proposals of secreted protein biomarkers overexpressed in cancer tissue and serum [J]. Proc Natl Acad Sci USA, for revision of the T,N,and M descriptors and consequent 2003,100(6):3410-3415. stage groupings in the forthcoming (seventh) edition of the [9] Koopmann J,Buckhaults P,Brown DA,et al. Serum TNM classification of malignant tumours[j]. J Thorac Oncol, macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers [J]. Clin Cancer Res, 2007,2(8):694-705. [2] Bauskin AR,Brown DA,Kuffner T,et al. Role of macrophage 2004,10(7):2386-2392. inhibitory cytokine-1 in tumorigenesis and diagnosis of [10] Liang JJ,Kimchi ET,Staveley-O Carroll KF,et al. Diagnostic and prognostic biomarkers in pancreatic carcinoma cancer [J].Cancer Res,2006,66(10):4983-4986. [3] Koopmann J,Rosenzweig CN,Zhang Z,et al. Serum markers in patients with resectable pancreatic adenocarcinoma: [J]. Int J Clin Exp Pathol,2009,2(1):1-10. macrophage inhibitory cytokine 1 versus CA19-9 [J].Clin Cancer Res,2006,12(2):442-446. [11] Fu C. Application and development study of the serum immunoassay kit [D].Beijing:Peking Union Medical [4] Fu C,Wang H,Qi J,et al. Application of serum College,2011. [. macrophage inhibitory cytokine-1 in pancreatic cancer [J]. Oncology Progress,2011,9(2):204-208.[,, [12] [D]. :,2011.] Ma ZH,Shen QB,Fei SW,et al. Significance of combined,. 1 detection of CEA,CA125,CYFRA21-1 and NSE for lung [J].,2011,9(2):204-208.] cancer [J]. Chinese Journal of Immunology,2013,29(11): [5] Kim KK,Lee JJ,Yang Y,et al. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells[j]. 1174-1176. [,,,. CEA CA125 CYFRA21-1 NSE [J].,2013,29(11):1174-1176.] Carcinogenesis,2008,29(4):704-712. [13] Li YP,Wang Q,Zhao ZH,et al. Diagnostic value of combined [6] Wang XB,Li YF,Tian HM,et al. Development of monoclonal antibody and establishment of detecting system for macrophage inhibitory cytokine-1[j]. Oncology Progress, detection of serum tumor markers for lung cancer [J]. Chin Nucl Med Mol Imaging,2013,33(5):336-339. [,,,. 2011,9(4):361-366. [,,,. -1 2013,33(5):336-339.] [J]., 2015 24 5 425